Schick Kelly 4

4 · C4 Therapeutics, Inc. · Filed Mar 8, 2024

Form 4

Period: 2024-03-07

Chief People Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−92,000→ 0 total
Exercise: $37.46Exp: 2031-01-10→ Common Stock (92,000 underlying)
Award
Stock Option (Right to Buy)
2024-03-07+78,500→ 78,500 total
Exercise: $19.00Exp: 2032-02-13→ Common Stock (78,500 underlying)
Award
Stock Option (Right to Buy)
2024-03-07+92,000→ 92,000 total
Exercise: $19.00Exp: 2031-01-10→ Common Stock (92,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−78,500→ 0 total
Exercise: $22.71Exp: 2032-02-13→ Common Stock (78,500 underlying)

Footnotes (3)

[F1]On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
[F2]25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
[F3]The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.

Documents

1 file